Alison’s areas of expertise include design and execution of pharmacoepidemiology research studies, predictive analysis using machine learning, and natural language processing techniques. She is also an experienced R programmer. Most of her research has been in oncology indications and she has also been involved in research into other chronic conditions. Alison has published research in peer-review journal articles and has presented work at various international conferences, including the International Society of Pharmacoepidemiology and Outcomes Research (ISPOR) and the American Society of Hematology (ASH).
Prior to joining Evidera, Alison worked as an epidemiologist in the Healthcare division at GlobalData. There her work primarily involved sourcing publically available data to forecast specific patient populations across numerous markets. Alison analyzed available data, population characteristics, and disease trends to employ appropriate statistical techniques to forecast relevant disease parameters. Her experience in patient population forecasting spans may disease areas, including infectious disease, oncology, immunology, neurology, and rare indications. She also has experience writing technical reports to accompany disease forecasts and in updating and maintaining an epidemiology database. Alison has experience in demographic research, having worked as a research associate at the University of Queensland (UQ). There her work primarily involved life-table construction and analysis, with the aim of characterizing the impact of changes in population on life expectancy. While at UQ, she also provided demographic assistance for the centre’s ongoing research projects and publications.
Prior to her work at UQ, Alison completed an internship in global oncology at IMS Health where she gained experience in tumour-specific epidemiology, statistics, and study design. She holds an MSc in demography and health from the London School of Hygiene and Tropical Medicine, and a BSc in biomedical science from the University of Warwick.